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Despite an improvement in diabetes care during the last 20
years, the number of diabetic patients starting renal
replacement therapy (RRT) has continued to increase in the
Western world. The aim was to study the incidence of
patients starting RRT in Denmark from 1990 to 2004. Data
were obtained from The Danish National Registry; Report on
Dialysis and Transplantation, where all patients actively
treated for end-stage renal disease have been registered
since 1990. The incidence of end-stage renal disease
increased until 2001. Thereafter the incidence stabilized on
130 per million people (pmp). The number of diabetic
patients starting RRT increased steadily from: 52 (number of
patients) in 1990, 113 in 1995, 150 in 2000, 168 in 2001, and
183 in 2002. However, during the years 2003 and 2004 this
number was significantly reduced by 15% to 156 and 155,
respectively. This was mainly due to a 22% reduction in the
number of non-insulin- treated (type II) diabetic patients
(number of patients): 98, 82, and 76 in 2002, 2003, and 2004,
respectively. The mean age in the background population,
the mean age in diabetic patients starting RRT and the
incidence of type I and type II diabetes increased during the
study period. The encouraging stabilization in the incidence
of diabetic patients referred for RRT observed in Denmark
could be the result of implementation of a multifactorial and
more intensive renoprotective intervention in patients with
diabetes and chronic progressive renal disease.
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Large clinical trials have demonstrated that several therapeu-
tic strategies in the treatment of diabetic patients are effective
in slowing or even preventing the progression of end-stage
renal disease (ESRD) as well as other diabetic complica-
tions.1–8 These studies have shown that intensive glycaemic
control, strict control of blood pressure, and blockade of the
renin–angiotensin system with angiotensin-converting en-
zyme inhibitors or angiotensin II receptor antagonists
significantly reduce the risk of development of microalbu-
minuria and nephropathy in patients with diabetes. This has
lead to the development of general recommendations
regarding the treatment of patients with diabetes in most
countries.9 Despite this improvement in diabetes care, the
number of new diabetic patients starting renal replacement
therapy (RRT) has increased in many countries, among
which are the United States, Europe, Australia, New Zealand,
and Japan.10–14 This could be due to the increased incidence
of non-insulin-dependent (type II) diabetes and lack of effect
of the diabetic treatment recommendations. Multipharmacy
and lifestyle changes are difficult to comply with and
therefore very few patients are able to benefit from such a
regimen.15 In a recent report from the Danish National
Registry, Report on Dialysis and Transplantation in Denmark
2004, the reported number of diabetic patients starting RRT
has decreased in the last 2 years. We therefore studied the
incidence of patients starting RRT in Denmark from 1990 to
2004.
RESULTS
The total population in Denmark including Greenland and
Faroe Islands increased from 5 237 771 on 1 January 1990 to
5 49 7 759 on 1 January 2004. The mean age in the population
increased linearly from 38.1 years to 39.1 years. During the
first part of the study period, the percentage of persons in
Denmark older than 60 years decreased. However, since 1996
the fraction of persons older than 60 years increased from
19.6 to 20.5%. The prevalence of ESRD, defined as the total
number of patients treated with dialysis or having a
functioning renal graft, increased every year from 385 per
million people (pmp) in 1990 to 752 pmp in 2004. Figure 1
shows the total incidence of ESRD from 1990 to 2004 and the
incidence among patients older than 60 years. The total
incidence of patients starting RRT was stable since 2001,
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whereas the incidence among people older than 60 years
declined since 2001. Looking into the distribution of various
diagnoses during the period, Figure 2 shows that diabetic
nephropathy was the single most important cause of ESRD
during the entire period. The incidence in diabetic patients
(type I and type II) starting RRT increased threefold from
1990 to 2002 (Figure 3). However, during the years 2003 and
2004 the incidence was reduced by 15%. The decreased
incidence of patients with diabetes was mainly due to a
reduction of patients with type II diabetes whereas the
incidence of type I was stable during the last 4 years. The
incidence curve with prediction limits for 2003 and 2004
(Figure 4) shows that the decreased incidence in 2004 is
significant with Po0.05. In 1990, 18% of the patients starting
RRT had diabetic nephropathy. Successively the fraction of
diabetic patients increased every year until 1995, from when,
the fraction has remained generally stable around 22%. The
male/female ratio (63/37) was unchanged during the period
and similar in diabetic and non-diabetic patients. Table 1
shows the mean age in type I, type II, and non-diabetic
patients during four time intervals. Overall, the mean age of
patients starting RRT increased during the study period. In
type II diabetic patients the mean age also increased
significantly in 2003 and 2004 where the incidence of ESRD
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Figure 1 | Incidence of ESRD in patients 460 years, o60 years,
and all patients.
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Figure 2 | Renal diagnoses from 1990 to 2004.
1990 1992 1994 1996 1998 2000 2002 2004
Year
0
5
10
15
20
25
30
35
In
ci
de
nc
e 
(p.
m.
p.)
Type 1 and type 2
Type 1
Type 2
Figure 3 | Incidence of diabetic patients starting RRT from
1990–2004 (pmp).
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Figure 4 | Incidence and 95% prediction limits of diabetic
patients with ESRD from 1990–2004.
Table 1 | Mean age in patients starting renal replacement
therapy from 1990 to 2004 (years (s.d.))
1990–1994 1995–1999 2000–2002 2003–2004
Patients with type I
diabetes
47.2713 50.5713* 53.8714* 51.3714
Patients with type II
diabetes
62.878 65.3710* 66.8710* 69.079*
Patients without
diabetes
54.7717 58.2717* 61.7717* 61.8717
s.d., standard deviation.
*Po0.05 compared with previous time period.
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owing to diabetes was decreasing. The mean age in type I
diabetic patients and non-diabetic patients was not signifi-
cantly different in 2003–2004 compared to 2000–2002. The
differences between the other time periods were all
significant.
The prevalence of diabetes is increasing in Denmark as
well as internationally.16,17 The incidence of childhood type I
diabetes has increased 1.23% annually during the last 30 years
in Denmark.18 The prevalence of type II diabetes increased
20–60% during the last 20 years and among persons who are
60 years old in Denmark every third man and every fourth
woman have either diabetes or impaired glucose tolerance.19
The prevalence of known diabetes in Denmark has been
estimated on the basis of national registers to approximately
100 000 in 1996, 130 000 in 1999, and 150 000 patients in
2004.19–21 The percentage of patients with ESRD who are
older than 60 years has been stable since 1999, comprising
approximately 60% of the total number of patients starting
RRT.
DISCUSSION
The worldwide prevalence of diabetes has increased drama-
tically22 and a concomitant increase in the incidence of
diabetic patients requiring RRT has been seen in the Western
world. In Europe, the incidence of diabetic patients with
ESRD increased form 14.8 pmp in 1991–1992 to 26.9 pmp in
1999–2000.14 In the United States, the incidence of ESRD
owing to diabetes increased from 62.5 to 134 pmp during the
1990s.16 In Denmark, we have now observed a stabilization of
the total incidence of ESRD since 2001 and a decreased
incidence of diabetic patients starting RRT during the years
2003 and 2004. This was mainly due to a reduction in the
incidence of patients registered with type II diabetes. It is
likely that some insulin-treated type II diabetic patients in the
Danish database have been misclassified as having type I
diabetes, because of start of insulin treatment. If this is the
case, the true incidence of type I diabetes is less than reported
and the observed stable incidence of type I diabetic patients
progressing to ESRD is probably underestimated. The stable
crude incidence of type I diabetic patients progressing to
ESRD is also influenced by the increasing incidence of type I
diabetes in the background population and may therefore be
further underestimated. As the diagnosis ‘diabetic nephro-
pathy’ was clinical and only rarely based on kidney biopsy, it
cannot be ruled out that some of the patients classified as
unknown in the database did have diabetic nephropathy.
However, the same groups of persons in the regional centers
have been reporting during the entire study period and the
methods of registration have been unchanged. Thus, our
observations do not seem to be explained by registration bias
of diabetic patients starting RRT from 1990 to 2004.
Our observations could theoretically be explained by
several factors. First, before 1990 diabetic patients were in
many cases not offered RRT because of limited capacity in
the dialysis units for patients with complicating chronic
diseases other than renal failure. In such a scenario, a new
steady state should be reached with a higher but stable
incidence of RRT patients after a certain period of time. As
unlimited access to RRT has been a reality in Denmark for at
least 15 years, such a steady state should have been reached
many years ago. Secondly, changes in the incidence of
diabetes in the study period could play a role. The incidence
of both type I and type II diabetes did, however, increase in
the background population during the study period, and an
increase in the incidence of RRT would therefore be expected.
In contrast, the incidence of ESRD due to diabetes stabilized
and tended to decrease. Thirdly, changes in the pattern of
referral towards not treating elderly diabetic patients could
play a role. The percentage of patients older than 80 years
when starting RRT has, however, increased linearly from 2%
in 1997 to 10% in 2004 and the mean age of diabetic patients
starting RRT increased during the entire study period.
Furthermore it is the general opinion among Danish
nephrologists that the criteria for starting dialysis are similar
between the different nephrological centers. As the mean age
in the background population increased, neither was this an
explanation of the stabilized incidence of RRT owing to
diabetes. Random variation is unlikely to explain the
observed changes in the incidence of RRT observed during
the last 2 years. The incidence in 2003 and 2004 was
significantly different than the expected incidence. Further-
more, our observation finds support from other registries
where similar trends have been reported. In the United States,
the incidence of ESRD owing to diabetes has been stable at
approximately 145–150 pmp since 2001.23 A study from
Holland also showed stabilization in the total incidence of
ESRD since 2001. In that study, the incidence of type II
diabetic patients with ESRD was still increasing whereas the
incidence of ESRD due to type I diabetes was decreasing.24
Finally, in a cohort study of type I diabetic patients in
Finland, which aimed at estimating the long-term risk of
developing ESRD, it was suggested that the prognosis
regarding ESRD had improved during the last four decades.25
Our observation of a declining incidence of RRT in diabetic
patients could at least in part be due to the more intensive
and multifactorial treatment that have been implemented
during the last 10–15 years. In the early 1980s, two landmark
studies showed that in patients with type I diabetes and
proteinuria, treatment of hypertension slowed down the
decrease in glomerular filtration rate.26,27 Since then, several
randomized trials have documented that treatment of
hypertension and use of angiotensin-converting enzyme
inhibitors and angiotensin receptor antagonists has been
effective in slowing or even preventing progression of
nephropathy in both type I and type II diabetic patients.1,2,6–8
The implementation of these therapeutic strategies should
have the potential to reduce the burden of ESRD due to
diabetes, but so far this has only been demonstrated in short-
time follow-up. Several reports have also documented that
lack of adherence to pharmacological treatment and lifestyle
changes is a common problem.15,28,29 Serious deficits in the
care of diabetic patients with pre-terminal renal failure still
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exists in the United States as well as in Europe,30,31 and even
better results preventing ESRD might be accessible. Fagerudd
et al.32 studied the implementation of guidelines for
prevention of diabetic nephropathy in type I diabetic patients
and found that 79% did not achieve the target blood pressure
p140/p90 mm Hg. Good glyceamic control defined as
Hba1c o7.5% was only registered in 24% of the patients.
In our study, we do not have information about duration of
diabetes, co-morbidity, blood pressure, or metabolic control
and therefore the level of adherence is unknown.
We conclude that even though both the mean age and the
incidence of type I and type II diabetes in the background
population increased, the total incidence of ESRD has been
unchanged during the last 4 years, and that the incidence of
diabetic patients starting RRT in Denmark has stabilized and
possibly declined for the past 2 years. These encouraging
observations may be the result of the implementation of a
multifactorial and more intensive renoprotective interven-
tion, in most patients with chronic progressive renal diseases,
and in particular in patients with diabetes.
MATERIALS AND METHODS
Data were obtained from The Danish National Registry; Report on
Dialysis and Transplantation, where all patients actively treated for
ESRD have been registered since 1990. Once a year all regional
centers refer data to a central database at the national registry, using
identical software programs. The material is checked for errors, and
appropriate corrections are made in agreement with the reporting
centers. The response rate is 100%. No private clinics exist. A
national report is prepared, and data are transferred to the registry
maintained by the European Dialysis and Transplantation Associa-
tion (ERA-EDTA). Data regarding the number and age distribution
of the Danish population were obtained from the national database
Statistics Denmark.
Analysis
Incidence rates were studied annually from 1990 to 2004. Incidence
was expressed as number of patients pmp starting RRT (dialysis or
renal transplantation). For analysis, patients were subdivided
according to age using a cut-off value of 60 years and to renal
diagnoses using ERA-EDTA codes.
Statistical analysis
The incidence was fitted into a linearly model. Using the computer
program Statistica 6.0 a linear regression line with the years
1990–2002 on the x axis and the incidence of diabetic patients
starting RRT on the y axis was made. The 95% prediction limits were
calculated and the incidence of diabetic patients starting RRT in
2003 and 2004 were considered significantly different if they were
higher or lower than the line of the 95% prediction limit.
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